← LIGAND PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($1.6m) | $12.6m | $143.3m | $629.3m | ($3.0m) | $57.1m | ($33.4m) | $52.2m | ($4.0m) | $124.5m | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| Depreciation, Depletion and Amortization | $11.3m | $11.7m | $14.7m | $18.4m | $25.7m | $51.1m | $51.5m | $36.5m | $35.2m | $33.8m | $32.9m | |
| Depreciation | $200k | $400k | $900k | $1.5m | $1.8m | $3.9m | $3.8m | $2.9m | $2.3m | $1.0m | $33.2m | |
| Amortization of Debt Issuance Costs and Discounts | $10.9m | $11.6m | $44.0m | $30.0m | $23.1m | $16.7m | $734k | $240k | $486k | $1.3m | — | |
| Amortization of Intangible Assets | $10.6m | $11.3m | $15.8m | $16.9m | $23.4m | $47.2m | $51.5m | $36.5m | $35.2m | $33.8m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | ($8.6m) | $30.5m | $10.0m | ($15.8m) | $21.9m | $31.3m | |
| Share-based Payment Arrangement, Noncash Expense | $18.9m | $24.9m | $20.8m | $24.5m | $30.7m | $38.8m | $60.3m | $25.7m | $41.1m | $46.8m | $53.3m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $999k | $10.1m | $3.8m | $4.4m | $1.5m | $6.0m | $8.2m | $4.5m | $5.1m | $9.6m | — | |
| Goodwill and Intangible Asset Impairment | — | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| Goodwill, Impairment Loss | $0 | — | — | — | — | — | — | — | — | — | $4.1m | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | — | — | — | — | $30.6m | $6.2m | — | |
| Impairment of Intangible Assets, Finite-lived | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Income (Loss) from Equity Method Investments | ($23.1m) | ($2.0m) | $42.3m | $2.9m | — | — | $0 | ($1.8m) | ($12.8m) | $0 | — | |
| Nonoperating Income (Expense) | ($35.9m) | ($10.8m) | $9.6m | ($10.4m) | ($36.4m) | ($31.6m) | $33.0m | $51.7m | $25.1m | $118.0m | — | |
| Other Nonoperating Income (Expense) | $2.7m | $5.2m | ($6.3m) | ($6.0m) | ($108k) | ($8.9m) | $4.2m | ($2.0m) | ($54.9m) | ($89k) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $8.5m | $8.4m | $29.5m | ($25.5m) | $26.1m | $28.6m | ($55.3m) | $2.6m | $6.5m | $21.7m | ($25.8m) | |
| Increase (Decrease) in Inventories | $244k | $843k | $2.6m | $2.1m | $17.8m | $427k | ($12.1m) | $10.9m | ($9.6m) | ($5.0m) | $5.2m | |
| Inventory Write-down | $0 | $0 | $0 | $0 | $0 | $0 | $1.1m | $200k | $200k | $0 | — | |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | $0 | $0 | — | — | — | $53.1m | — | |
| Other Operating Income (Expense), Net | — | — | — | — | — | — | $0 | $0 | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | $63.0m |
$93.6m
+48.52%
|
$194.1m
+107.40%
|
($29.3m)
-115.12%
|
$54.6m
+286.07%
|
$78.8m
+44.36%
|
$137.8m
+74.94%
|
$49.6m
-64.04%
|
$97.0m
+95.75%
|
$49.4m
-49.14%
|
$131.7m
+166.85%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.9m | $2.2m | $887k | $2.6m | $4.5m | $8.8m | $17.9m | $3.5m | $1.8m | $452k | ($12.0m) | |
| Gain (Loss) on Investments | — | — | — | $2.9m | ($16.9m) | ($4.0m) | $28.5m | $46.4m | $75.0m | $18.4m | ($47.3m) | |
| Unrealized Gain (Loss) on Investments | ($1.1m) | $144k | $48k | $256k | ($212k) | ($221k) | ($85k) | $212k | $45k | $181k | $29k | |
| Payments to Acquire Businesses, Net of Cash Acquired | $92.5m | $26.7m | $5.9m | $11.8m | $404.9m | $0 | $0 | $10.4m | $0 | $0 | ($96.2m) | |
| Payments for (Proceeds from) Other Investing Activities | $0 | — | — | $4.7m | ($1.9m) | $1.2m | $960k | $0 | $0 | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($143.2m) | ($84.2m) | ($423.3m) | $466.9m | $231.6m | $30.5m | $163.6m | ($11.7m) | ($143.7m) | ($377.3m) | ($144.8m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | $0 | — | $217.7m | $27.3m | $222.2m | $155.8m | $260.9m | $76.9m | $0 | $0 | ($113.3m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | ($7.3m) | $4.2m | $0 | $0 | — | — | |
| Payments for Repurchase of Common Stock | $3.9m | $2.0m | $122.9m | $453.0m | $78.0m | $0 | $0 | $0 | $0 | $15.0m | — | |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | $0 | $0 | $37.1m | $0 | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $1.5m |
($7.5m)
-596.57%
|
$328.6m
+4467.74%
|
($485.2m)
-247.65%
|
($310.5m)
+35.99%
|
($137.8m)
+55.64%
|
($276.0m)
-100.34%
|
($59.9m)
+78.28%
|
$97.1m
+262.04%
|
$428.2m
+340.83%
|
$950.3m
+121.91%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $0 | $0 | ($215k) | $83k | $0 | $0 | $0 | $0 | $49.4m | $102.6m | $1.0b | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $119.8m | $72.3m | $48.0m | $19.5m | $45.0m | $23.0m | $72.3m | $174.9m | $1.0b | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $0 | $0 | ($215k) | $83k | $0 | $0 | $0 | $0 | ($1.2m) | $2.4m | ($995k) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $6.4m | $4.5m | $20.2m | $3.0m | $3.0m | $33.8m | $3.2m | $22.4m | $65.6m | $47.5m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $1.8m | $1.8m | $1.5m | $5.8m | $4.5m | $3.0m | $1.4m | $288k | $263k | $321k | — | |
| Income Taxes Paid, Net | $38k | $157k | $341k | $103.8m | $2.1m | $3.7m | $11.6m | $8.8m | $19.2m | $7.8m | — | |
| Additional Financial Items | ||||||||||||
| Deconsolidation, Gain (Loss), Amount | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| Derivative, Gain (Loss) on Derivative, Net | — | — | ($1.8m) | — | — | $0 | $0 | ($250k) | ($15.1m) | $0 | — | |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax | $731k | $144k | $0 | $256k | ($212k) | ($221k) | ($85k) | $212k | $45k | $181k | — | |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax | $731k | $0 | $0 | — | — | — | — | — | — | — | — | |
| Equity Securities, FV-NI, Gain (Loss) | — | — | $50.2m | — | — | — | $0 | $0 | $25.8m | ($90.7m) | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | — | — | $0 | $0 | ($25.8m) | $90.7m | — | |
| Gain (Loss) on Disposition of Assets | ($183k) | — | — | $812.8m | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Intangible Assets | — | — | — | $812.8m | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Business | $1.1m | — | — | — | $17.1m | $0 | $0 | $2.1m | $0 | $0 | — | |
| Gain (Loss) on Sale of Derivatives | — | — | — | — | — | — | — | $300k | — | — | — | |
| General and Administrative Expense | $26.6m | $28.7m | $37.7m | $41.9m | $64.4m | $57.5m | $70.1m | $52.8m | $78.7m | $92.4m | — | |
| Goodwill | $72.2m | $86.0m | $86.6m | $95.2m | $189.7m | $181.2m | $105.7m | $103.4m | $105.2m | $101.5m | $4.1m | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($5.2m) | $53.8m | ($4.0m) | $124.5m | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($2.4m) | $12.6m | $143.3m | — | — | — | — | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($28.1m) | ($1.7m) | — | — | — | |
| Income Tax Expense (Benefit) | $10.3m | $44.7m | $30.0m | $167.3m | ($7.6m) | ($9.8m) | $41.2m | $9.8m | $6.5m | $34.5m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $3.0m | $4.7m | — | |
| Investment Income, Interest | — | — | — | $28.4m | $8.1m | $886k | $2.0m | $7.7m | $8.1m | $13.7m | — | |
| Operating Costs and Expenses | $65.1m | $73.0m | $87.7m | $126.0m | $177.7m | $198.2m | $193.2m | $121.5m | $189.7m | $227.1m | — | |
| Operating Lease, Expense | — | — | — | $2.1m | $2.1m | $2.6m | $700k | $1.4m | $1.3m | $900k | — | |
| Payments for Repurchase of Warrants | — | — | $30.1m | $380k | $0 | $18.4m | $0 | $0 | — | — | — | |
| Realized Investment Gains (Losses) | $2.4m | $831k | $2.6m | $41k | — | — | — | — | — | — | — | |
| Unrealized Gain (Loss) on Derivatives | ($1.1m) | $144k | $48k | $256k | ($212k) | ($221k) | ($85k) | $250k | ($20.0m) | $1.0m | — |